Briacell Therap (BCTX) Competitors

Briacell Therap logo
$3.11 -0.05 (-1.58%)
As of 12:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BCTX vs. FHTX, MOLN, ENGN, OTLK, and VYGR

Should you buy Briacell Therap stock or one of its competitors? Briacell Therap's main competitors and comparable companies include Foghorn Therapeutics (FHTX), Molecular Partners (MOLN), enGene (ENGN), Oncobiologics (OTLK), and Voyager Therapeutics (VYGR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Briacell Therap compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Foghorn Therapeutics presently has a consensus target price of $6.14, indicating a potential upside of 250.02%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Foghorn Therapeutics is more favorable than Briacell Therap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Foghorn Therapeutics has a net margin of 8.40% compared to Briacell Therap's net margin of 0.00%. Foghorn Therapeutics' return on equity of -13.46% beat Briacell Therap's return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics8.40% -13.46% 4.63%
Briacell Therap N/A -178.17%-143.77%

Foghorn Therapeutics has a beta of 3.22, suggesting that its stock price is 222% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Briacell Therap has lower revenue, but higher earnings than Foghorn Therapeutics. Briacell Therap is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$30.91M3.40-$74.28M$0.0725.07
Briacell TherapN/AN/A-$34.90M-$9.16N/A

In the previous week, Foghorn Therapeutics had 3 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for Foghorn Therapeutics and 0 mentions for Briacell Therap. Foghorn Therapeutics' average media sentiment score of 0.31 beat Briacell Therap's score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Foghorn Therapeutics Neutral
Briacell Therap Neutral

Summary

Foghorn Therapeutics beats Briacell Therap on 14 of the 15 factors compared between the two stocks.

How does Briacell Therap compare to Molecular Partners?

Briacell Therap (NASDAQ:BCTX) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Briacell Therap's average media sentiment score of 0.00 equaled Molecular Partners'average media sentiment score.

Company Overall Sentiment
Briacell Therap Neutral
Molecular Partners Neutral

Briacell Therap has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Briacell Therap has higher earnings, but lower revenue than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Briacell TherapN/AN/A-$34.90M-$9.16N/A
Molecular Partners$5.65M18.12-$74.41M-$1.68N/A

Molecular Partners' return on equity of -80.03% beat Briacell Therap's return on equity.

Company Net Margins Return on Equity Return on Assets
Briacell TherapN/A -178.17% -143.77%
Molecular Partners N/A -80.03%-62.56%

Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 230.37%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts plainly believe Molecular Partners is more favorable than Briacell Therap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Molecular Partners
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Molecular Partners beats Briacell Therap on 9 of the 12 factors compared between the two stocks.

How does Briacell Therap compare to enGene?

Briacell Therap (NASDAQ:BCTX) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

enGene has a consensus price target of $10.75, indicating a potential upside of 516.05%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Briacell Therap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
enGene
2 Sell rating(s)
4 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.50

Briacell Therap has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, enGene has a beta of -0.24, indicating that its share price is 124% less volatile than the broader market.

enGene's return on equity of -55.79% beat Briacell Therap's return on equity.

Company Net Margins Return on Equity Return on Assets
Briacell TherapN/A -178.17% -143.77%
enGene N/A -55.79%-45.17%

enGene is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Briacell TherapN/AN/A-$34.90M-$9.16N/A
enGeneN/AN/A-$117.30M-$2.07N/A

In the previous week, enGene had 9 more articles in the media than Briacell Therap. MarketBeat recorded 9 mentions for enGene and 0 mentions for Briacell Therap. enGene's average media sentiment score of 0.49 beat Briacell Therap's score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company Overall Sentiment
Briacell Therap Neutral
enGene Neutral

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

enGene beats Briacell Therap on 11 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oncobiologics' return on equity of 0.00% beat Briacell Therap's return on equity.

Company Net Margins Return on Equity Return on Assets
OncobiologicsN/A N/A -254.82%
Briacell Therap N/A -178.17%-143.77%

Oncobiologics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

In the previous week, Oncobiologics had 3 more articles in the media than Briacell Therap. MarketBeat recorded 3 mentions for Oncobiologics and 0 mentions for Briacell Therap. Oncobiologics' average media sentiment score of 0.67 beat Briacell Therap's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the media.

Company Overall Sentiment
Oncobiologics Positive
Briacell Therap Neutral

Briacell Therap has lower revenue, but higher earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncobiologics$1.35M65.46-$62.42M-$0.77N/A
Briacell TherapN/AN/A-$34.90M-$9.16N/A

Oncobiologics currently has a consensus price target of $5.20, indicating a potential upside of 1,332.51%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than Briacell Therap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Oncobiologics beats Briacell Therap on 9 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Voyager Therapeutics?

Briacell Therap (NASDAQ:BCTX) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Briacell Therap has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Briacell TherapN/AN/A-$34.90M-$9.16N/A
Voyager Therapeutics$40.37M2.41-$119.72M-$1.73N/A

Voyager Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,497.44%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Briacell Therap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Briacell Therap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

In the previous week, Voyager Therapeutics had 10 more articles in the media than Briacell Therap. MarketBeat recorded 10 mentions for Voyager Therapeutics and 0 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.00 beat Voyager Therapeutics' score of -0.21 indicating that Briacell Therap is being referred to more favorably in the media.

Company Overall Sentiment
Briacell Therap Neutral
Voyager Therapeutics Neutral

Briacell Therap has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -416.32%. Voyager Therapeutics' return on equity of -63.42% beat Briacell Therap's return on equity.

Company Net Margins Return on Equity Return on Assets
Briacell TherapN/A -178.17% -143.77%
Voyager Therapeutics -416.32%-63.42%-49.40%

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Briacell Therap has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

Voyager Therapeutics beats Briacell Therap on 11 of the 16 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCTX vs. The Competition

MetricBriacell TherapBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$27.15M$3.96B$7.48B$11.10B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-0.3423.7332.6829.17
Price / SalesN/A15.508.125.38
Price / CashN/A22.6520.7221.66
Price / Book1.744.194.353.55
Net Income-$34.90M-$23.99M$3.50B$393.99M
7 Day Performance-8.26%-8.11%-6.86%-7.60%
1 Month Performance-10.12%-13.46%-9.85%-10.97%
1 Year Performance-55.70%-6.94%-2.38%-8.48%

Briacell Therap Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCTX
Briacell Therap
0.0309 of 5 stars
$3.11
-1.6%
N/A-55.2%$27.15MN/AN/A31
FHTX
Foghorn Therapeutics
3.7327 of 5 stars
$2.09
+10.0%
$6.14
+193.9%
-63.4%$124.10M$30.91M29.86106
MOLN
Molecular Partners
2.8603 of 5 stars
$3.06
-1.1%
$8.38
+174.1%
-41.0%$123.40M$5.65MN/A134
ENGN
enGene
4.0381 of 5 stars
$1.80
+7.8%
$11.05
+513.6%
-74.0%$120.63MN/AN/A82
OTLK
Oncobiologics
1.8354 of 5 stars
$0.48
+4.4%
$5.20
+981.1%
-79.5%$117.10M$1.35MN/A17

Related Companies and Tools


This page (NASDAQ:BCTX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners